Table 5. Parameters tested in the sensitivity analysis.
| Parameter | Baseline estimate | Range |
|---|---|---|
| Imatinib price per 100 mg | £12.98 | £6.49–£12.98a |
| 12-month rate of response loss (accelerated phase study cohort) | 22.5% | 13.6–31.5%b |
| Nine-monthly rate of response loss (blast crisis study cohort) | 46.1% | 30.9–61.3%c |
| Utility of imatinib in CytR/CHR/PHR | 0.91 | 0.73–1.00d |
| Utility of imatinib in ACCEL | 0.58 | 0.15–1.00d |
| Utility of imatinib in BLAST | 0.38 | 0.02–0.74d |
| Discount rate for QALYs | 1.5% | 0–6e |
| Discount rate for costs | 6% | 0–10e |
a
A maximum price discount of 50% might be possible in the long-term future.
b
Based on 95% confidence interval for 12-month duration of haematological response (trial 0109).
c
Based on 95% confidence interval for 9-month duration of haematological response (trial 0102).
d
Range of estimates from clinician panel.
e
National Institute for Clinical Excellence, 2001.